Clinical Trials - Desmoid Tumor Research Foundation
Menu

Clinical Trials

Please be aware that this page may not always be current. Updated information regarding clinical trials can be found searching for “desmoid tumor” at the National Cancer Institute’s website.

THE FOLLOWING ARE ONGOING OR RECENTLY CLOSED TRIALS INCLUDING DESMOIDS:

Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: September 8, 2017

Sponsor:

Grupo Espanol de Investigacion en Sarcomas

ClinicalTrials.gov #:

NCT03275818

Genders:

Sexes Eligible for Study: All

Ages:

6 Months to 80 Years   (Child, Adult, Senior)

Description:

Conditions:   Tumor, Desmoplastic Small Round Cell, Adult;   Tumor, Desmoplastic Small Round Cell, Childhood;   Sarcoma, Ewing;   Sarcoma;   Desmoid
Intervention:   Drug: nab paclitaxel
Sponsor:   Grupo Espanol de Investigacion en Sarcomas
Recruiting
More Details

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Recruiting Status:

-

Last Updated:

Last Update Posted: June 20, 2017

Sponsor:

University of Colorado, Denver

ClinicalTrials.gov #:

NCT02955446

Genders:

-

Ages:

-

Description:

Conditions:   Neoplasm;   Desmoid Tumor
Intervention:   Drug: PF-03084014
Sponsors:   University of Colorado, Denver;   Pfizer
No longer available
More Details

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Recruiting Status:

Not yet recruiting

Last Updated:

Last Update Posted: September 27, 2017

Sponsor:

National Cancer Institute (NCI)

ClinicalTrials.gov #:

NCT02961374

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 69 Years   (Adult, Senior)

Description:

Conditions:   Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
More Details

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: October 16, 2017

Sponsor:

Centre Oscar Lambret

ClinicalTrials.gov #:

NCT02867033

Genders:

Sexes Eligible for Study: All

Ages:

Child, Adult, Senior

Description:

Condition:   Aggressive Fibromatosis
Interventions:   Procedure: biopsy;   Other: biobank constitution;   Procedure: Coloscopy;   Procedure: Blood sampling (facultative);   Other: Pain evaluation;   Procedure: Tumor biobank realization
Sponsors:   Centre Oscar Lambret;   Ligue contre le cancer, France;   Institut Curie;   Hôpital de la Timone
Recruiting
More Details

Optional Sub-study to Intraoperative Imaging With ICG Registry

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: July 20, 2016

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

ClinicalTrials.gov #:

NCT02651246

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Conditions:   Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer;   Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer;   Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Intervention:   Other: data collection
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting
More Details

Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients

Recruiting Status:

Unknown status

Last Updated:

Last Update Posted: September 11, 2015

Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

ClinicalTrials.gov #:

NCT02547831

Genders:

Sexes Eligible for Study: All

Ages:

Child, Adult, Senior

Description:

Condition:   Desmoid-type Fibromatosis
Intervention:   Other: Observational approach
Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   Ministero della Salute, Italy
Unknown status
More Details

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Recruiting Status:

Active, not recruiting

Last Updated:

Last Update Posted: July 13, 2016

Sponsor:

Yonsei University

ClinicalTrials.gov #:

NCT02495519

Genders:

Sexes Eligible for Study: All

Ages:

10 Years and older   (Child, Adult, Senior)

Description:

Condition:   Fibromatosis
Intervention:   Drug: Imatinib
Sponsor:   Yonsei University
Active, not recruiting
More Details

Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Treatment

Recruiting Status:

Completed

Last Updated:

Last Update Posted: November 16, 2017

Sponsor:

University Hospital, Strasbourg, France

ClinicalTrials.gov #:

NCT02476305

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Desmoid Tumors
Intervention:   Device: "cryoprobes"
Sponsor:   University Hospital, Strasbourg, France
Completed
More Details

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: January 13, 2017

Sponsor:

Vanderbilt-Ingram Cancer Center

ClinicalTrials.gov #:

NCT02374931

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Conditions:   Deep Fibromatosis/Desmoid Tumor;   Familial Adenomatous Polyposis
Interventions:   Radiation: F-18 16 Alpha-Fluoroestradiol;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting
More Details

Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets

Recruiting Status:

Unknown status

Last Updated:

Last Update Posted: February 2, 2015

Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

ClinicalTrials.gov #:

NCT02353429

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Desmoid Type-fibromatosis
Intervention:   Drug: Toremifene
Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   Associazione Italiana per la Ricerca sul Cancro
Unknown status
More Details

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version

Recruiting Status:

Not yet recruiting

Last Updated:

Last Update Posted: February 3, 2015

Sponsor:

michal roll

ClinicalTrials.gov #:

NCT02354560

Genders:

Sexes Eligible for Study: All

Ages:

10 Years to 17 Years   (Child)

Description:

Condition:   FAP-Familial Adenomatous Polyposis
Intervention:   Drug: Erythromycin
Sponsor:   michal roll
Not yet recruiting
More Details

Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: January 18, 2017

Sponsor:

Janis, Jeffrey E, MD

ClinicalTrials.gov #:

NCT02228889

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 99 Years   (Adult, Senior)

Description:

Conditions:   Hernia, Ventral;   Intestinal Fistula;   Fibromatosis, Abdominal
Interventions:   Procedure: Abdominal wall reconstruction with Strattice;   Other: Assess pain intensity at last office visit preoperatively;   Other: Assess pain interference at last office visit preoperatively;   Other: Assess physical functioning at last office visit preoperatively;   Other: Assess patient quality of life at last office visit preoperatively;   Other: Assess patient pain intensity postoperatively;   Other: Assess pain interference postoperatively;   Other: Assess physical functioning postoperatively;   Other: Assess quality of life postoperatively;   Other: Assess hernia recurrence at 30 days postoperatively;   Other: Assess bulge at 30 days postoperatively;   Other: Assess Surgical Site Occurrences at 30 days postoperatively;   Other: Assess hernia recurrence at 1 year postoperatively;   Other: Assess bulge at 1 year postoperatively;   Other: Assess Surgical Site Occur
More Details

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis

Recruiting Status:

Unknown status

Last Updated:

Last Update Posted: June 26, 2014

Sponsor:

michal roll

ClinicalTrials.gov #:

NCT02175914

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   FAP-Familial Adenomatous Polyposis
Intervention:   Drug: Erythromycin
Sponsor:   michal roll
Unknown status
More Details

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Recruiting Status:

Active, not recruiting

Last Updated:

Last Update Posted: October 31, 2017

Sponsor:

National Cancer Institute (NCI)

ClinicalTrials.gov #:

NCT02066181

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Desmoid-Type Fibromatosis
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting
More Details

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: June 12, 2017

Sponsor:

AeRang Kim

ClinicalTrials.gov #:

NCT02076906

Genders:

Sexes Eligible for Study: All

Ages:

up to 30 Years   (Child, Adult)

Description:

Conditions:   Relapsed Pediatric Solid Tumors;   Refractory Pediatric Solid Tumors;   Tumors Located in Bone or Soft Tissue in Close Proximity to Bone;   Rhabdomyosarcoma;   Ewing Sarcoma;   Osteosarcoma;   Neuroblastoma;   Wilms Tumor;   Hepatic Tumor;   Germ Cell Tumor;   Desmoid Tumor
Intervention:   Device: Magnetic Resonance High Intensity Focused Ultrasound
Sponsor:   AeRang Kim
Recruiting
More Details

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Recruiting Status:

Active, not recruiting

Last Updated:

Last Update Posted: October 19, 2017

Sponsor:

National Cancer Institute (NCI)

ClinicalTrials.gov #:

NCT01981551

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 120 Years   (Adult, Senior)

Description:

Conditions:   Desmoid Tumors;   Aggressive Fibromatosis
Intervention:   Drug: PF-03084014
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting
More Details

Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: October 31, 2013

Sponsor:

michal roll

ClinicalTrials.gov #:

NCT01898416

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Conditions:   The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an;   Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After;   Surgical Resection
Intervention:   Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Sponsor:   michal roll
Recruiting
More Details

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: October 5, 2017

Sponsor:

Institut Bergonié

ClinicalTrials.gov #:

NCT01876082

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Progressive Desmoids Tumors
Interventions:   Drug: PAZOPANIB treatment;   Drug: Active Comparator: Vinblastine and Methotrexate
Sponsor:   Institut Bergonié
Recruiting
More Details

A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

Recruiting Status:

Completed

Last Updated:

Last Update Posted: July 27, 2017

Sponsor:

OncoMed Pharmaceuticals, Inc.

ClinicalTrials.gov #:

NCT01608867

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 90 Years   (Adult, Senior)

Description:

Condition:   Solid Tumors
Intervention:   Biological: OMP-54F28
Sponsors:   OncoMed Pharmaceuticals, Inc.;   Bayer
Completed
More Details

Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

Recruiting Status:

Completed

Last Updated:

Last Update Posted: May 17, 2016

Sponsor:

Children's Oncology Group

ClinicalTrials.gov #:

NCT01567046

Genders:

Sexes Eligible for Study: All

Ages:

up to 30 Years   (Child, Adult)

Description:

Conditions:   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma
Intervention:   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Completed
More Details

A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome

Recruiting Status:

Completed

Last Updated:

Last Update Posted: January 31, 2011

Sponsor:

Triemli Hospital

ClinicalTrials.gov #:

NCT01286662

Genders:

Sexes Eligible for Study: All

Ages:

Child, Adult, Senior

Description:

Conditions:   Gardner Syndrome;   Colorectal Carcinoma;   Desmoid Tumor
Intervention:  
Sponsor:   Triemli Hospital
Completed
More Details

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: October 19, 2017

Sponsor:

National Cancer Institute (NCI)

ClinicalTrials.gov #:

NCT01273168

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 120 Years   (Adult, Senior)

Description:

Conditions:   Hormone Receptor-Positive Breast;   Gynecologic;   Desmoid;   Hormone Receptor-Positive Neoplasms
Intervention:   Drug: Z-Endoxifen
Sponsor:   National Cancer Institute (NCI)
Recruiting
More Details

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: April 7, 2017

Sponsor:

Maine Medical Center

ClinicalTrials.gov #:

NCT01265030

Genders:

Sexes Eligible for Study: All

Ages:

up to 29 Years   (Child, Adult)

Description:

Condition:   Desmoid Tumor
Intervention:   Drug: Sirolimus
Sponsors:   Maine Medical Center;   Desmoid Tumor Research Foundation;   Pfizer
Recruiting
More Details

Study to Evaluate Imatinib in Desmoid Tumors

Recruiting Status:

Completed

Last Updated:

Last Update Posted: May 3, 2017

Sponsor:

Heidelberg University

ClinicalTrials.gov #:

NCT01137916

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Conditions:   Aggressive Fibromatosis;   Desmoid Tumor
Intervention:   Drug: Imatinib
Sponsors:   Heidelberg University;   Novartis
Completed
More Details

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

Recruiting Status:

Completed

Last Updated:

Last Update Posted: June 7, 2012

Sponsor:

Centre Oscar Lambret

ClinicalTrials.gov #:

NCT01046487

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Cancer
Interventions:   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 );   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2);   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3);   Procedure: Blood sampling
Sponsor:   Centre Oscar Lambret
Completed
More Details

Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors

Recruiting Status:

Withdrawn

Last Updated:

Last Update Posted: April 20, 2017

Sponsor:

Children's Hospital of Philadelphia

ClinicalTrials.gov #:

NCT00978146

Genders:

Sexes Eligible for Study: All

Ages:

up to 21 Years   (Child, Adult)

Description:

Conditions:   Desmoid Tumors;   Fibromatosis
Intervention:   Drug: Hydroxyurea
Sponsor:   Children's Hospital of Philadelphia
Withdrawn
More Details

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Recruiting Status:

Active, not recruiting

Last Updated:

Last Update Posted: August 23, 2017

Sponsor:

Italian Sarcoma Group

ClinicalTrials.gov #:

NCT00928525

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 80 Years   (Adult, Senior)

Description:

Conditions:   Advanced Desmoid Tumor;   Advanced Chondrosarcoma
Intervention:   Drug: Imatinib Mesylate
Sponsor:   Italian Sarcoma Group
Active, not recruiting
More Details

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Recruiting Status:

Recruiting

Last Updated:

Last Update Posted: September 27, 2017

Sponsor:

Children's Oncology Group

ClinicalTrials.gov #:

NCT00919269

Genders:

Sexes Eligible for Study: All

Ages:

up to 50 Years   (Child, Adult)

Description:

Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting
More Details

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Recruiting Status:

Completed

Last Updated:

Last Update Posted: March 5, 2014

Sponsor:

INSYS Therapeutics Inc

ClinicalTrials.gov #:

NCT00538850

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Cancer
Interventions:   Drug: Fentanyl sublingual spray;   Drug: Placebo
Sponsors:   INSYS Therapeutics Inc;   National Cancer Institute (NCI)
Completed
More Details

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Recruiting Status:

Completed

Last Updated:

Last Update Posted: January 20, 2016

Sponsor:

Memorial Sloan Kettering Cancer Center

ClinicalTrials.gov #:

NCT00474994

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 120 Years   (Adult, Senior)

Description:

Conditions:   Adult Malignant Fibrous Histiocytoma of Bone;   Desmoid Tumor;   Endometrial Cancer;   Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Intervention:   Drug: sunitinib malate
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI);   Dana-Farber Cancer Institute
Completed
More Details

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Recruiting Status:

Completed

Last Updated:

Last Update Posted: August 30, 2016

Sponsor:

UNICANCER

ClinicalTrials.gov #:

NCT00287846

Genders:

Sexes Eligible for Study: All

Ages:

18 Years to 120 Years   (Adult, Senior)

Description:

Condition:   Desmoid Tumor
Intervention:   Drug: imatinib mesylate
Sponsor:   UNICANCER
Completed
More Details

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

Recruiting Status:

Completed

Last Updated:

Last Update Posted: July 25, 2014

Sponsor:

Children's Oncology Group

ClinicalTrials.gov #:

NCT00003019

Genders:

Sexes Eligible for Study: All

Ages:

up to 21 Years   (Child, Adult)

Description:

Condition:   Desmoid Tumor
Interventions:   Drug: methotrexate;   Drug: vinblastine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   Children's Cancer Group
Completed
More Details

Toremifene in Treating Patients With Desmoid Tumors

Recruiting Status:

Completed

Last Updated:

Last Update Posted: July 10, 2013

Sponsor:

Lutheran General Hospital

ClinicalTrials.gov #:

NCT00002595

Genders:

Sexes Eligible for Study: All

Ages:

16 Years and older   (Child, Adult, Senior)

Description:

Condition:   Desmoid Tumor
Interventions:   Drug: toremifene;   Procedure: conventional surgery
Sponsor:   Lutheran General Hospital
Completed
More Details

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

Recruiting Status:

Active, not recruiting

Last Updated:

Last Update Posted: April 21, 2017

Sponsor:

Children's Oncology Group

ClinicalTrials.gov #:

NCT00068419

Genders:

Sexes Eligible for Study: All

Ages:

up to 18 Years   (Child, Adult)

Description:

Condition:   Desmoid Tumor
Interventions:   Drug: tamoxifen citrate;   Drug: sulindac;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting
More Details

Radiation Therapy in Treating Patients With Aggressive Fibromatoses

Recruiting Status:

Completed

Last Updated:

Last Update Posted: August 27, 2013

Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

ClinicalTrials.gov #:

NCT00030680

Genders:

Sexes Eligible for Study: All

Ages:

16 Years and older   (Child, Adult, Senior)

Description:

Condition:   Desmoid Tumor
Intervention:   Radiation: radiation therapy
Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
Completed
More Details

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Recruiting Status:

Completed

Last Updated:

Last Update Posted: March 15, 2012

Sponsor:

National Institutes of Health Clinical Center (CC)

ClinicalTrials.gov #:

NCT00020579

Genders:

Sexes Eligible for Study: All

Ages:

18 Years and older   (Adult, Senior)

Description:

Condition:   Cancer
Intervention:   Drug: entinostat
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Completed
More Details
  TOP